[Exceptional pancytopenia secondary to treatment with pegylated interferon and ribavirin].
Wikman Jorgensen
P E
PE
Jover Díaz
F M
FM
Cuadrado Pastor
J M
JM
D000328:Adult; D000998:Antiviral Agents / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D000068256:Darbepoetin alfa; D004359:Drug Therapy, Combination; D004921:Erythropoietin / Q000031:analogs & derivatives / Q000627:therapeutic use; D000069585:Filgrastim; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use; D019698:Hepatitis C, Chronic / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage / Q000009:adverse effects* / Q000494:pharmacology / Q000627:therapeutic use; D007501:Iron / Q000627:therapeutic use; D008297:Male; D010198:Pancytopenia / Q000139:chemically induced* / Q000503:physiopathology; D011092:Polyethylene Glycols / Q000008:administration & dosage / Q000009:adverse effects* / Q000494:pharmacology / Q000627:therapeutic use; D053633:Receptor, Interferon alpha-beta / Q000187:drug effects / Q000502:physiology; D011994:Recombinant Proteins; D012254:Ribavirin / Q000008:administration & dosage / Q000627:therapeutic use*; D015398:Signal Transduction
D000998:Antiviral Agents; C507964:IFNAR1 protein, human; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D004921:Erythropoietin; D016179:Granulocyte Colony-Stimulating Factor; D053633:Receptor, Interferon alpha-beta; D000068256:Darbepoetin alfa; D011092:Polyethylene Glycols; D012254:Ribavirin; D007501:Iron; D000069585:Filgrastim; C100416:peginterferon alfa-2a